<DOC>
	<DOCNO>NCT00176865</DOCNO>
	<brief_summary>This study test clinical outcome preparative regimen fludarabine ( FLU ) , anti-thymocyte globulin ( ATG ) /or Campath , melphalan ; follow hematopoietic stem cell transplant , post transplant regimen Cyclosporin A ( CsA ) patient immunologic histiocytic disorder . The researcher hypothesize regimen positive effect post transplant engraftment incidence graft-versus-host-disease ( GVHD ) . Patients randomize biologically one 3 arm base upon donor availability : ( ) human leukocyte antigen ( HLA ) genotypic match sibling donor , ( b ) HLA phenotypic match unrelated peripheral blood stem cell ( PBSC ) donor , ( c ) two HLA 0-2 antigen mismatch unrelated cord blood donor ( double cord ) .</brief_summary>
	<brief_title>Stem Cell Transplant Immunologic Histiocytic Disorders</brief_title>
	<detailed_description>Prior transplantation , subject receive Melphalan , Fludarabine Anti-Thymocyte Globulin ( ATG ) Campath . These three drug give subject help new stem cell take grow . On day transplantation , subject receive stem cell transfuse via intravenous ( IV ) catheter . After stem cell transplantation , subject give Cyclosporin A ( CsA ) mycophenolate mofetil ( MMF ) reduce risk graft-versus-host disease , complication occur donor 's stem cell react patient .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Histiocytosis , Langerhans-Cell</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients immunodeficiency histiocytic disorder 035 year age acceptable stem cell donor disease characteristic define follow : Patients histocytic disorder ( hemophagocytic lymphohistiocytosis etiology refractory Langerhans cell histiocytosis ) meet eligibility criterion myeloablative transplant procedure Patients immunodeficiency disorder residual immune function may require fully myeloablative preparative regimen patient ineligible standard myeloablative preparative regimen ( form severe combine immunodeficiency [ SCID ] , immunodeficiency T cell defect ) Patients immunodeficiency disorder poor outcome myeloablative stem cell transplant ( include , limited , common variable immunodeficiency [ CVID ] , Wiskott Aldrich Syndrome [ WAS ] &gt; 5 year age , ataxia telangiectasia ) Patients immunodeficiencies histocytic disorder require second stem cell transplant ( SCT ) reason Karnofsky Lansky performance score &lt; 70 Glomerular filtration rate ( GFR ) &lt; 30 % predict Cardiac function &lt; 50 % normal echocardiogram Serum creatinine &gt; 2x normal age/weight Pregnant lactating female Active serious infection adequate course therapy preSCT . Any patient acquire immune deficiency syndrome ( AIDS ) AIDSrelated complex ( ARC ) human immunodeficiency virus ( HIV ) seropositivity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Stem cell transplant</keyword>
	<keyword>immunodeficiency</keyword>
	<keyword>donor lymphocyte infusion</keyword>
</DOC>